Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470920 · ClinicalTrials.gov registry record · NA
Genetic Testing Decision Aid
A NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 2
- Study locations
NCT05470920 is a NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 350 participants, above the 44-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (695% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT05470920, a NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
Conditions Studied
Interventions
- BEHAVIORAL Electronic Decision Aid
- BEHAVIORAL Pre-Test Genetic Counseling
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Mass General at North Shore Cancer Center - Danvers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05470920
The ClinicalTrials.gov registry entry for NCT05470920 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (695% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Electronic Decision Aid is the first listed.
NCT05470920 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05470920 about?
NCT05470920 is a clinical study titled "Genetic Testing Decision Aid". This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
What is the current status of trial NCT05470920?
This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2022-10-14. Estimated completion is 2026-12-31.
What conditions does trial NCT05470920 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma, Epithelial Ovarian Carcinoma.
What interventions are being tested in trial NCT05470920?
The interventions under investigation include: Electronic Decision Aid (BEHAVIORAL), Pre-Test Genetic Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT05470920?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05470920 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
RECRUITING · Phase 2
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Pancreas Adenocarcinoma
All registered trials for this condition
Epithelial Ovarian Carcinoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.